BioWorld

April 15, 2005

View Archived Issues

FDA Seen As More Stringent Regarding Drug Safety Issues

Read More

Xsira Licenses Clinical-Stage Adenosine-Based Compound

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Stressgen Sells Bioreagents Unit To Better Focus On Lead Product

Concentrating its efforts on its lead drug, HspE7, Stressgen Biotechnologies Corp. agreed to divest its bioreagents business in a move that adds a bit of capital to its coffers. (BioWorld Today) Read More

Deal Transforming Bionaut From Platform To Products

Read More